+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Prevnar"

Prevnar 13 - Product Thumbnail Image

Prevnar 13

  • Report
  • December 2018
  • 16 Pages
  • Global
From
Pneumovax 23 - Product Thumbnail Image

Pneumovax 23

  • Report
  • December 2018
  • 14 Pages
  • Global
From
Disease Analysis: Pneumococcal Vaccines - Product Thumbnail Image

Disease Analysis: Pneumococcal Vaccines

  • Report
  • May 2021
  • 45 Pages
  • Global
From
From
From
Pneumococcal Vaccine Market Report and Forecast 2024-2032 - Product Thumbnail Image

Pneumococcal Vaccine Market Report and Forecast 2024-2032

  • Report
  • November 2023
  • 160 Pages
  • Global
From
Loading Indicator

Prevnar is a vaccine used to protect against pneumococcal disease, a type of bacterial infection that can cause serious illnesses such as pneumonia, meningitis, and sepsis. It is recommended for infants and young children, as well as adults over the age of 65. Prevnar is a conjugate vaccine, meaning it contains a combination of bacterial antigens that stimulate the body's immune system to produce antibodies. The vaccine is administered in a series of four doses, with the first dose given at two months of age. The Prevnar market is highly competitive, with several major players offering their own versions of the vaccine. These include Pfizer, Merck, GlaxoSmithKline, Sanofi Pasteur, and AstraZeneca. Each company has its own unique formulation of the vaccine, which is designed to provide the best protection against pneumococcal disease. Show Less Read more